CLINICAL HANDBOOK OF SCHIZOPHRENIA

19. Other Medications 195Citrome, L., Casey, D. E., Daniel, D. G., Wozniak, P., Kochan, L. D., & Tracy, K. A. (2004). Adjunctivedivalproex and hostility among patients with schizophrenia receiving olanzapine orrisperidone. Psychiatric Services, 55(3), 290–294.Citrome, L., Jaffe, A., Levine, J., & Allingham, B. (2002). Use of mood stabilizers among patients withschizophrenia, 1994–2001. Psychiatric Services, 53(10), 1212.Dursun, S. M., & Deakin, J. F. (2001). Augmenting antipsychotic treatment with lamotrigine ortopiramate in patients with treatment-resistant schizophrenia: A naturalistic case-series outcomestudy. Journal of Psychopharmacology, 15(4), 297–301.Emsley, R., Oosthuizen, P., & van Rensburg, S. J. (2003). Clinical potential of omega-3 fatty acids inthe treatment of schizophrenia. CNS Drugs, 17(15), 1081–1091.Evins, A. E., Cather, C., Deckersbach, T., Freudenreich, O., Culhane, M. A., Olm-Shipman, C. M., etal. (2005). A double-blind placebo-controlled trial of bupropion sustained-release for smokingcessation in schizophrenia. Journal of Clinical Psychopharmacology, 25(3), 218–225.Joy, C. B., Mumby-Croft, R., & Joy, L. A. (2003). Polyunsaturated fatty acid supplementation forschizophrenia.Cochrane Database Systematic Reviews, 2, CD001257.Keck, P. E., Jr., McElroy, S. L., Strakowski, S. M., & West, S. A. (1994). Pharmacologic treatment ofschizoaffective disorder. Psychopharmacology, 114(4), 529–538.Kramer, M. S., Vogel, W. H., DiJohnson, C., Dewey, D. A., Sheves, P., Cavicchia, S., et al. (1989). Antidepressantsin “depressed” schizophrenic inpatients: A controlled trial. Archives of General Psychiatry,46, 922–928.Kremer, I., Vass, A., Gorelik, I., Bar, G., Blanaru, M., Javitt, D. C., et al. (2004). Placebo-controlledtrial of lamotrigine added to conventional and atypical antipsychotics in schizophrenia. BiologicalPsychiatry, 56(6), 441–446.Lehman, A. F., Kreyenbuhl, J., Buchanan, R. W., Dickerson, F. B., Dixon, L. B., Goldberg, R., et al.(2004).The Schizophrenia Patient Outcomes Research Team (PORT): Updated treatment recommendations2003. Schizophrenia Bulletin, 30(2), 193–217.Leucht, S., Kissling, W., & McGrath, J. (2004). Lithium for schizophrenia revisited: A systemic reviewand meta-analysis of randomized controlled trials. Journal of Clinicial Psychiatry, 65, 177–186.Leucht, S., McGrath, J., White, P., & Kissling, W. (2002). Carbamazepine for schizophrenia andschizoaffective psychoses. Cochrane Database Systematic Reviews, 3, CD001258.Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., et al.(2005). Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators: Effectivenessof antipsychotic drugs in patients with chronic schizophrenia. New England Journal ofMedicine, 353(12), 1209–1223.Müller-Siecheneder, F., Müller, M. J., Hillert, A., Sgegedi, A., Wetzel, H., & Benkert, O. (1998).Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combinedpsychotic and depressive syndrome. Journal of Clinical Psychopharmacology, 18, 111–120.Peet, M., & Stokes, C. (2005). Omega-3 fatty acids in the treatment of psychiatric disorders. Drugs,65(8), 1051–1059.Pommepuy, N., & Januel, D. (2002) Catatonia: Resurgence of a concept: A review of the internationalliterature. Encephale, 28(6), 481–492.Siris, S. G., Morgan, V., Fagerstrom, R., Rifkin, A., & Cooper, T. B. (1987). Adjunctive imipramine inthe treatment of postpsychotic depression. Archives of General Psychiatry, 44, 533–539.Wolkowitz, O. M., & Pickar, D. (1991). Benzodiazepines in the treatment of schizophrenia: A reviewand reappraisal. American Journal of Psychiatry, 148, 714–726.